medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2023-223medsovet-7685Research ArticleДЕРМАТОЛОГИЯDERMATOLOGYОбоснование применения препаратов с декспантенолом в наружной терапии дерматозов у детей и взрослыхRationale for the use of dexpanthenol drugs as part of the external therapy of dermatoses in children and adultshttps://orcid.org/0000-0003-3420-4442СтадниковаА. С.StadnikovaA. S.

Стадникова Антонина Сергеевна – кандидат медицинских наук, ассистент кафедры дерматовенерологии с курсом косметологии факультета непрерывного медицинского образования Медицинского института, РУДН; врач-дерматовенеролог, ДГКБ им. З.А. Башляевой.

117198, Москва, ул. Миклухо-Маклая, д. 6; 125373, Москва, ул. Героев Панфиловцев, д. 28

Antonina S. Stadnikova - Cand. Sci. (Med.), Assistant of the Department of Dermatovenerology with the course of Cosmetology of the Faculty of Continuing Medical Education of the Medical Institute, Peoples' Friendship University of Russia; Dermatovenerologist, Bashlyaeva City Children's Clinical Hospital.

6, Miklukho-Maklai St., Moscow, 117198; 28, Geroev Panfilovtsev St., Moscow, 125373

tonya-st@yandex.ruhttps://orcid.org/0000-0003-3261-6718ТамразоваО. Б.TamrazovaO. В.

Тамразова Ольга Борисовна - доктор медицинских наук, профессор кафедры дерматовенерологии с курсом косметологии факультета непрерывного медицинского образования Медицинского института, РУДН; руководитель центра аллергодерматозов, ДГКБ им. З.А. Башляевой.

117198, Москва, ул. Миклухо-Маклая, д. 6; 125373, Москва, ул. Героев Панфиловцев, д. 28

Olga В. Tamrazova - Dr. Sci. (Med.), Рrofessor of the Department of Dermatovenerology with the course of Cosmetology of the Faculty of Continuing Medical Education of the Medical Institute, Peoples' Friendship University of Russia; Head of the Allergodermatosis Center, Bashlyaeva City Children's Clinical Hospital.

6, Miklukho-Maklai St., Moscow, 117198; 28, Geroev Panfilovtsev St., Moscow, 125373

anait_tamrazova@mail.ruhttps://orcid.org/0000-0002-7571-5460НовикГ. А.NovikG. A.

Новик Геннадий Айзикович - доктор медицинских наук, профессор, заведующий кафедрой педиатрии имени профессора И.М. Воронцова.

194100, Санкт-Петербург, ул. Литовская, д. 2

Gennady А. Novik - Dr. Sci. (Med.), Professor, Head of the Department of Pediatrics named after Professor I.M. Vorontsov, St Petersburg State Pediatric Medical University.

2, Litovskaya St., St Petersburg, 194100

ga_novik@mail.ruhttps://orcid.org/0000-0003-4615-7356БаграмоваГ. Э.BagramovaG. Е.

Баграмова Гаянэ Эрнстовна – доктор медицинских наук, профессор кафедры дерматовенерологии с курсом косметологии факультета непрерывного медицинского образования Медицинского института.

117198, Москва, ул. Миклухо-Маклая, д. 6

Gayane Е. Bagramova - Dr. Sci. (Med.), Рrofessor of the Department of Dermatovenerology with the course of Cosmetology of the Faculty of Continuing Medical Education of the Medical Institute, Peoples' Friendship University of Russia.

6, Miklukho-Maklai St., Moscow, 117198

bagramovaga@mail.ruhttps://orcid.org/0000-0002-2425-9346ВоробьеваА. С.VorobevaA. S.

Воробьева Александра Сергеевна – кандидат медицинских наук, заведующий 1-м педиатрическим отделением.

125373, Москва, ул. Героев Панфиловцев, д. 28

Alexandra S. Vorobeva - Cand. Sci. (Med.), Head of Paediatrics Department No 1, Bashlyaeva City Children's Clinical Hospital.

28, Geroev Panfilovtsev St., Moscow, 125373

dr.alexa@bk.ruРоссийский университет дружбы народов; Детская городская клиническая больница имени З.А. БашляевойРоссияPeoples' Friendship University of Russia; Bashlyaeva City Children's Clinical HospitalRussian FederationСанкт-Петербургский государственный педиатрический медицинский университетРоссияSt Petersburg State Pediatric Medical UniversityRussian FederationРоссийский университет дружбы народовРоссияPeoples' Friendship University of RussiaRussian FederationДетская городская клиническая больница имени З.А. БашляевойРоссияBashlyaeva City Children's Clinical HospitalRussian Federation202327072023012140148Copyright © Стадникова А.С., Тамразова О.Б., Новик Г.А., Баграмова Г.Э., Воробьева А.С., 20232023Стадникова А.С., Тамразова О.Б., Новик Г.А., Баграмова Г.Э., Воробьева А.С.Stadnikova A.S., Tamrazova O.В., Novik G.A., Bagramova G.Е., Vorobeva A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7685

Нарушение кожного барьера играет основную роль в развитии многих кожных заболеваний и состояний, таких как сухая кожа, чувствительная кожа, атопический дерматит, контактный дерматит и т. д. Целями топической терапии больных атопическим дерматитом являются не только подавление воспалительной реакции в коже, но также и восстановление разрушенного защитного липидного барьера эпидермиса. Декспантенол синтезирован в середине прошлого века и представляет собой производное пантотеновой кислоты. Топический декспантенол хорошо проникает в кожу, где превращается в пантотеновую кислоту, входящую в состав кофермента А, и таким образом участвует в регуляции синтеза жирных кислот и сфинголипидов - компонентов рогового слоя эпидермиса. Таким образом, пантотеновая кислота необходима для нормального функционирования эпителия. Топический декспантенол улучшает гидратацию кожи за счет своих гигроскопических свойств и способности удерживать влагу. Гидратирующий эффект взаимосвязан с его способностью восстанавливать эпидермальный барьер кожи. Также декспантенол усиливает дифференцировку корнеоцитов и синтез липидов, стимулируя регенерацию эпидермиса. По данным исследований, эффективность декспантенола сопоставима с эффективностью глюкокортикостероидов слабой степенью активности. Декспантенол является активным ингредиентом препарата Пантодерм, который выпускается в форме крема и мази. Содержание декспантенола в мази и креме Пантодерм составляет 5%. В статье приведены собственные клинические примеры лечения пациентов с атопическим дерматитом и назначением комбинированной терапии. В выводах заключение о том, что использование комбинации топических глюкокортикостероидов и декспантенола может повысить эффективность терапии больных атопическим дерматитом.

Impaired skin barrier plays a major role in the development of many skin diseases and conditions such as dry skin, sensitive skin, atopic dermatitis, contact dermatitis, etc. The topical therapy aims at not only suppressing the inflammatory response in the skin, but also at regenerating the destroyed protective epidermal lipid barrier in atopic dermatitis patients. Dexpanthenol was produced by synthesis in the middle of the last century and is a derivative of pantothenic acid. Topical dexpanthenol is well absorbed through the skin, where it is converted into pantothenic acid, a component of coenzyme A, and thus participates in the regulation of the synthesis of fatty acids and sphingolipids, components of the stratum corneum. Therefore, pantothenic acid is essential for the normal functioning of the epithelium. Topical dexpanthenol improves skin hydration due to its hygroscopic properties and ability to retain moisture. The hydrating effect is interrelated with its capacity to regenerate the epidermal barrier of the skin. Dexpanthenol also enhances the differentiation of corneocytes and lipid synthesis, stimulating the regeneration of the epidermis. Numerous studies show that the efficacy of dexpanthenol is comparable to the efficacy of glucocorticosteroids by a weak degree of activity. Dexpanthenol is the active ingredient of Pantoderm, which is available as cream and ointment. Pantoderm ointment and cream contain 5% dexpanthenol. The article presents its own clinical reports of the treatment of patients with atopic dermatitis and administration of the combination therapy. It may be concluded that the use of topical glucocorticosteroids combined with dexpanthenol can increase the effectiveness of therapy in patients with atopic dermatitis.

декспантенолпантотеновая кислотадерматозыатопический дерматитбарьерная функция кожигидратация кожиdexpanthenolpantothenic aciddermatosisatopic dermatitisskin barrier functionskin hydrationReferencesKelly G.S. Pantothenic acid. Monograph. Altern Med Rev. 2011;16:263-274. https://pubmed.ncbi.nlm.nih.gov/21951027/.Kelly G.S. Pantothenic acid. Monograph. Altern Med Rev. 2011;16:263-274. https://pubmed.ncbi.nlm.nih.gov/21951027/.Lanska D.J. The discovery of niacin, biotin, and pantothenic acid. Ann Nutr Metab. 2012;61(3):246-253. https://doi.org/10.1159/000343115.Lanska D.J. The discovery of niacin, biotin, and pantothenic acid. Ann Nutr Metab. 2012;61(3):246-253. https://doi.org/10.1159/000343115.Stuttgen G., Krause H. Die percutane absorption von tritium-markiertem panthenol bei mensch und tier. Arch Klin Exp Derm. 1960;209:578-82. https://doi.org/10.1007/BF00477492.Stuttgen G., Krause H. Die percutane absorption von tritium-markiertem panthenol bei mensch und tier. Arch Klin Exp Derm. 1960;209:578-82. https://doi.org/10.1007/BF00477492.Wollina U., Kubicki J. Multiaktive eigenschaften von dexpanthenol-haltigen externa. Kosm Med. 2007;28:122-128. Available at: https://www.researchgate.net/publication/263278521_Multiaktive_Eigenschaften_von_Dexpanthenol-haltigen_Externa.Wollina U., Kubicki J. Multiaktive eigenschaften von dexpanthenol-haltigen externa. Kosm Med. 2007;28:122-128. Available at: https://www.researchgate.net/publication/263278521_Multiaktive_Eigenschaften_von_Dexpanthenol-haltigen_Externa.Abiko Y., Tomikawa M., Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol (Kyoto). 1969;15(1):59-69. https://doi.org/10.5925/jnsv1954.15.59.Abiko Y., Tomikawa M., Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol (Kyoto). 1969;15(1):59-69. https://doi.org/10.5925/jnsv1954.15.59.Proksch E., Jensen J.M. Dexpanthenol. In Barel A.O., Paye M., Maibach H.I., ed. Handbook of Cosmetic Science and Technology. 2nd ed. New York, London: Taylor & Francis Group; 2006, p. 399-406. https://doi.org/10.1201/b14400.Proksch E., Jensen J.M. Dexpanthenol. In Barel A.O., Paye M., Maibach H.I., ed. Handbook of Cosmetic Science and Technology. 2nd ed. New York, London: Taylor & Francis Group; 2006, p. 399-406. https://doi.org/10.1201/b14400.Proksch E., Holleran W.M., Menon G.K., Elias P.M., Feingold K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol. 1993;128(5):473-482. https://doi.org/10.1111/j.1365-2133.1993.tb00222.x.Proksch E., Holleran W.M., Menon G.K., Elias P.M., Feingold K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol. 1993;128(5):473-482. https://doi.org/10.1111/j.1365-2133.1993.tb00222.x.Slyshenkov V.S., Rakowska M., Moiseenok A.G., Wojtczak L. Pantothenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Free Radic Biol Med. 1995;19(6):767-772. https://doi.org/10.1016/0891-5849(95)00084-B.Slyshenkov V.S., Rakowska M., Moiseenok A.G., Wojtczak L. Pantothenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Free Radic Biol Med. 1995;19(6):767-772. https://doi.org/10.1016/0891-5849(95)00084-B.Proksch E., Nissen H.P. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. J Dermatolog Treat. 2002;13(4):173-178. https://doi.org/10.1080/09546630212345674.Proksch E., Nissen H.P. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. J Dermatolog Treat. 2002;13(4):173-178. https://doi.org/10.1080/09546630212345674.Wollina U. Zur klinischen wirksamkeit von dexpanthenol. Kosm Med. 2001;22:180-186. Available at: https://www.researchgate.net/publication/263278358_Zur_klinischen_Wirksamkeit_von_Dexpanthenol.Wollina U. Zur klinischen wirksamkeit von dexpanthenol. Kosm Med. 2001;22:180-186. Available at: https://www.researchgate.net/publication/263278358_Zur_klinischen_Wirksamkeit_von_Dexpanthenol.Eggensperger H. Multiaktive Wirkstoffe fur Kosmetika: Teil II. Seifen Ole Fette Wachse J. 1994;120(9):534-538. Available at: https://www.econbiz.de/Record/multiaktive-wirkstoffe-f%C3%BCr-kosmetika-teil-ii-eggensperger/10006801140.Eggensperger H. Multiaktive Wirkstoffe fur Kosmetika: Teil II. Seifen Ole Fette Wachse J. 1994;120(9):534-538. Available at: https://www.econbiz.de/Record/multiaktive-wirkstoffe-f%C3%BCr-kosmetika-teil-ii-eggensperger/10006801140.Verse T., Klocker N., Riedel F., Pirsig W., Scheithauer M.O. Dexpanthenol - Nasenspray vs. Nasensalbe. HNO. 2004;52:611-615. https://doi.org/10.1007/s00106-003-0961-4.Verse T., Klocker N., Riedel F., Pirsig W., Scheithauer M.O. Dexpanthenol - Nasenspray vs. Nasensalbe. HNO. 2004;52:611-615. https://doi.org/10.1007/s00106-003-0961-4.Abdel Hamid M., Kassem A.A., Mattha A.G., El-Khatib G. Evaluation of the biological activity of some medicated solidified sodium stearate-based sticks (SSSS). Drug Dev Ind Pharm. 1984;(10):685-697. https://doi.org/10.3109/03639048409041415.Abdel Hamid M., Kassem A.A., Mattha A.G., El-Khatib G. Evaluation of the biological activity of some medicated solidified sodium stearate-based sticks (SSSS). Drug Dev Ind Pharm. 1984;(10):685-697. https://doi.org/10.3109/03639048409041415.Hauptmann S., Schafer H., Fritz A., Hauptmann P. The growth modifying effect of wound ointments on cell cultures. Hautarzt. 1992;43(7):432-435. Available at: https://pubmed.ncbi.nlm.nih.gov/1506201.Hauptmann S., Schafer H., Fritz A., Hauptmann P. The growth modifying effect of wound ointments on cell cultures. Hautarzt. 1992;43(7):432-435. Available at: https://pubmed.ncbi.nlm.nih.gov/1506201.Pittermann W., Schmitt M., Kietzmann M. Skin penetration properties of cosmetic formulations using a perfused bovine udder model. J Cosmet Sci. 1999;50(3):147-157. Available at: https://www.researchgate.net/publication/237400255_Skin_penetration_properties_of_cosmetic_formulations_using_a_perfused_bovine_udder_model.Pittermann W., Schmitt M., Kietzmann M. Skin penetration properties of cosmetic formulations using a perfused bovine udder model. J Cosmet Sci. 1999;50(3):147-157. Available at: https://www.researchgate.net/publication/237400255_Skin_penetration_properties_of_cosmetic_formulations_using_a_perfused_bovine_udder_model.Loden M. Treatments Improving Skin Barrier Function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.Loden M. Treatments Improving Skin Barrier Function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.Bensaude A. Treatment of anal fissure. Phlebologie. 1980;33(4):683-688. Available at: https://pubmed.ncbi.nlm.nih.gov/7454838/.Bensaude A. Treatment of anal fissure. Phlebologie. 1980;33(4):683-688. Available at: https://pubmed.ncbi.nlm.nih.gov/7454838/.Loden M. Treatments improving skin barrier function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.Loden M. Treatments improving skin barrier function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.Bjorklund S., Pham Q.D., Jensen L.B., Knudsen N.0., Nielsen L.D., Ekelund K. et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207-220. https://doi.org/10.1016/j.jcis.2016.06.054.Bjorklund S., Pham Q.D., Jensen L.B., Knudsen N.0., Nielsen L.D., Ekelund K. et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207-220. https://doi.org/10.1016/j.jcis.2016.06.054.Gimenez-Arnau A. Standards for the protection of skin barrier function. Curr Probl Dermatol. 2016;49:123-134. https://doi.org/10.1159/000441588.Gimenez-Arnau A. Standards for the protection of skin barrier function. Curr Probl Dermatol. 2016;49:123-134. https://doi.org/10.1159/000441588.Gehring W., Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung. 2000;50(7):659-663. https://doi.org/10.1055/s-0031-1300268.Gehring W., Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung. 2000;50(7):659-663. https://doi.org/10.1055/s-0031-1300268.Al-Momani T., Tawalbeh A., Shatnawi M., Tarawneh H., Sharadgah Z. Napkin dermatitis in babies: characteristics and efficacy of panthenol treatment. WJPMR. 2016;(2):22-24. Available at: https://www.wjpmr.com/home/article_abstract/50.Al-Momani T., Tawalbeh A., Shatnawi M., Tarawneh H., Sharadgah Z. Napkin dermatitis in babies: characteristics and efficacy of panthenol treatment. WJPMR. 2016;(2):22-24. Available at: https://www.wjpmr.com/home/article_abstract/50.Putet G., Guy B., Pages S., Gibaud C., Andres P., Sirvent A. et al. Effect of Bepanthen Ointment in the Prevention of Diaper Rash on Premature and Full-Term Babies: Open Pilot Study. Real Pediatr. 2000;52:21-28. Available at: https://www.huidherstel-pro.nl/studies/detail/effect-of-bepanthen-ointment-in-the-prevention-of-diaper-rash-on-premature-and-full-term-babies-open-pilot-studyPutet G., Guy B., Pages S., Gibaud C., Andres P., Sirvent A. et al. Effect of Bepanthen Ointment in the Prevention of Diaper Rash on Premature and Full-Term Babies: Open Pilot Study. Real Pediatr. 2000;52:21-28. Available at: https://www.huidherstel-pro.nl/studies/detail/effect-of-bepanthen-ointment-in-the-prevention-of-diaper-rash-on-premature-and-full-term-babies-open-pilot-studyPutet G., Guy B., Andres P., Sirvent A. Effect of BepanthenVR ointment in the prevention and treatment of diaper rash onpremature and full-term babies. Real Pediatr. 2001;63:33-38. Available at: https://www.researchgate.net/publication/285312774_Effect_of_Bepanthen_ointment_in_the_prevention_and_treatment_of_diaper_rash_on_premature_and_full-term_babies.Putet G., Guy B., Andres P., Sirvent A. Effect of BepanthenVR ointment in the prevention and treatment of diaper rash onpremature and full-term babies. Real Pediatr. 2001;63:33-38. Available at: https://www.researchgate.net/publication/285312774_Effect_of_Bepanthen_ointment_in_the_prevention_and_treatment_of_diaper_rash_on_premature_and_full-term_babies.Wolff H.H., Kieser M. Hamamelis in children with skin disorders and skin injuries: results of anobservational study. Eur J Pediatr. 2007;166(9):943-948. https://doi.org/10.1007/s00431-006-0363-1.Wolff H.H., Kieser M. Hamamelis in children with skin disorders and skin injuries: results of anobservational study. Eur J Pediatr. 2007;166(9):943-948. https://doi.org/10.1007/s00431-006-0363-1.Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.Gehring W., Gloor M. Der repetitive waschtest als modell zur beurteilung von hautschutzpraparaten am beispiel einer dexpanthenolhaltigen formulierung. Akt Dermatol. 2001;27(8/9):279-284. https://doi.org/10.1055/s-2001-17290.Gehring W., Gloor M. Der repetitive waschtest als modell zur beurteilung von hautschutzpraparaten am beispiel einer dexpanthenolhaltigen formulierung. Akt Dermatol. 2001;27(8/9):279-284. https://doi.org/10.1055/s-2001-17290.Gehring W., Gloor M. Der effekt von dexpanthenol bei experimentell geschadigter haut. Z Hautkr. 2001;76(4):212-218. Available at: https://www.researchgate.net/publication/287423763_The_effect_of_dexpanthenole_in_experimentally_damaged_skin.Gehring W., Gloor M. Der effekt von dexpanthenol bei experimentell geschadigter haut. Z Hautkr. 2001;76(4):212-218. Available at: https://www.researchgate.net/publication/287423763_The_effect_of_dexpanthenole_in_experimentally_damaged_skin.Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https://doi.org/10.1016/j.jaad.2009.11.011.Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https://doi.org/10.1016/j.jaad.2009.11.011.Stettler H., Kurka P., Kandzora J., Pavel V., Breuer M., Macura-Biegun A. A new topical panthenol-containing emollient for maintenance treatment of childhood atopic dermatitis: Results from a multicenter prospective study. J Dermatol. Treat. 2017;28(8):774-779. https://doi.org/10.1080/09546634.2017.1328938.Stettler H., Kurka P., Kandzora J., Pavel V., Breuer M., Macura-Biegun A. A new topical panthenol-containing emollient for maintenance treatment of childhood atopic dermatitis: Results from a multicenter prospective study. J Dermatol. Treat. 2017;28(8):774-779. https://doi.org/10.1080/09546634.2017.1328938.Stables G.I., Wilkinson S.M. Allergic contact dermatitis due to panthenol. Contact Dermatitis. 1998;38(4):236-237. https://doi.org/10.1111/j.1600-0536.1998.tb05732.x.Stables G.I., Wilkinson S.M. Allergic contact dermatitis due to panthenol. Contact Dermatitis. 1998;38(4):236-237. https://doi.org/10.1111/j.1600-0536.1998.tb05732.x.Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2O12;26(8):1O45-1060. https//doi.org/10.1111/j.1468-3083.2012.04635.x.Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2O12;26(8):1O45-1060. https//doi.org/10.1111/j.1468-3083.2012.04635.x.Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https//doi.org/10.1016/j.jaad.2009.11.011.Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https//doi.org/10.1016/j.jaad.2009.11.011.Simpson E.L., Chalmers J.R., Hanifin J.M., Thomas K.S., Cork M.J., McLean W.H.I. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. https://doi.org/10.1016/j.jaci.2014.08.005.Simpson E.L., Chalmers J.R., Hanifin J.M., Thomas K.S., Cork M.J., McLean W.H.I. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. https://doi.org/10.1016/j.jaci.2014.08.005.Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https//pubmed.ncbi.nlm.nih.gov/22395588/.Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https//pubmed.ncbi.nlm.nih.gov/22395588/.Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. https//doi.org/10.1111/jdv.14891.Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. https//doi.org/10.1111/jdv.14891.Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М., Ильина Н.И., Амбарчян Э.Т., Аршинский М.И. и др. Атопический дерматит: клинические рекомендации. 2020. Режим доступа: https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf.Kubanov A.A., Namazova-Baranova L.S., Khaitov R.M., Il'ina N.I., Ambarchyan E.T., Arshinskiy M.I. et al. Atopic dermatitis: clinical guidelines. 2020. (In Russ.) Available at: https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf.Чикин В.В., Знаменская Л.Ф., Монахов К.Н., Заславский Д.В., Минеева А.А., Епишев Р.В. и др. Российская ассоциация аллергологов и клинических иммунологов: федеральные клинические рекомендации по диагностике и лечению атопического дерматита. 2013. Режим доступа: https://mzdrav.rk.gov.ru/file/Atopicheskij_dermatit_05052014_Klinicheskie_rekomendacii%281%29.pdf.Chikin V.V., Znamenskaya L.F., Monakhov K.N., Zaslavskiy D.V., Mineeva A.A., Epishev R.V. et al. Russian Association of Allergists and Clinical Immunologists: federal clinical guidelines for the diagnosis and treatment of atopic dermatitis.. 2013. (In Russ.) Available at: https://mzdrav.rk.gov.ru/file/Atopicheskij_dermatit_05052014_Klinicheskie_rekomendacii%281%29.pdf.Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. https://doi.org/10.1016/j.jaad.2014.03.023.Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. https://doi.org/10.1016/j.jaad.2014.03.023.Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588/.Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588/.Chiricozzi A., Belloni Fortina A., Galli E., Girolomoni G., Neri I., Ricci G. et al. Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergol Immunopathol. 2019;47(2):194-206. https://doi.org/10.1016/j.aller.2018.06.008.Chiricozzi A., Belloni Fortina A., Galli E., Girolomoni G., Neri I., Ricci G. et al. Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergol Immunopathol. 2019;47(2):194-206. https://doi.org/10.1016/j.aller.2018.06.008.Harcharik S., Emer J. Steroid-sparing properties of emollients in dermatology. Skin Therapy Lett. 2014;19(1):5-10. Available at: https://pubmed.ncbi. nlm.nih.gov/24570291/.Harcharik S., Emer J. Steroid-sparing properties of emollients in dermatology. Skin Therapy Lett. 2014;19(1):5-10. Available at: https://pubmed.ncbi. nlm.nih.gov/24570291/.Ebner F., Heller A., Rippke F., Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-433. https://doi.org/10.2165/00128071-200203060-00005.Ebner F., Heller A., Rippke F., Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-433. https://doi.org/10.2165/00128071-200203060-00005.Bielfeldt S., Wehmeyer A., Rippke F., Tausch I. Efficacy of a New Hand Care System (Cleansing Oil and Cream) in a Model of Irritation and by Atopic Hand Eczema. Derm Beruf Umwelt. 1998;46:159-165. Available at: https://chemport-n.cas.org//chemport-n/?APP=ftslink&action=reflink&-origin=npg&version=1.0&coi=1%3ACAS%3A528%3ADyaK1cXmtFCrur8%3D&md5=5737368d83b27b3c0b61a92055d19c92.Bielfeldt S., Wehmeyer A., Rippke F., Tausch I. Efficacy of a New Hand Care System (Cleansing Oil and Cream) in a Model of Irritation and by Atopic Hand Eczema. Derm Beruf Umwelt. 1998;46:159-165. Available at: https://chemport-n.cas.org//chemport-n/?APP=ftslink&action=reflink&-origin=npg&version=1.0&coi=1%3ACAS%3A528%3ADyaK1cXmtFCrur8%3D&md5=5737368d83b27b3c0b61a92055d19c92.Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. https://doi.org/10.1186/s12887-016-0607-9.Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. https://doi.org/10.1186/s12887-016-0607-9.Czarnowicki T., He H., Krueger J.G., Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. https://doi.org/10.1016/j.jaci.2018.10.032.Czarnowicki T., He H., Krueger J.G., Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. https://doi.org/10.1016/j.jaci.2018.10.032.Tokura Y., Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14-24. https://doi.org/10.1016/j.alit.2021.07.003.Tokura Y., Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14-24. https://doi.org/10.1016/j.alit.2021.07.003.Piquero-Casals J., Carrascosa J.M., Morgado-Carrasco D., Narda M., Trullas C., Granger C., Fabbrocini G. The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. Dermatol Ther. 2021;11(2):315-325. https://doi.org/10.1007/s13555-021-00495-y.Piquero-Casals J., Carrascosa J.M., Morgado-Carrasco D., Narda M., Trullas C., Granger C., Fabbrocini G. The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. Dermatol Ther. 2021;11(2):315-325. https://doi.org/10.1007/s13555-021-00495-y.Luk D., Hon K.L.E., Dizon M.V.C., Leong K.F., Tay Y.K., Koh M.J. et al. Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia. Dermatol Ther. 2021;11(1):275-291. https://doi.org/10.1007/s13555-020-00467-8.Luk D., Hon K.L.E., Dizon M.V.C., Leong K.F., Tay Y.K., Koh M.J. et al. Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia. Dermatol Ther. 2021;11(1):275-291. https://doi.org/10.1007/s13555-020-00467-8.

The authors declare that there are no conflicts of interest present.